STOCK TITAN

Nyxoah SA Ordinary Shares - NYXH STOCK NEWS

Welcome to our dedicated page for Nyxoah SA Ordinary Shares news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on Nyxoah SA Ordinary Shares stock.

Nyxoah SA Ordinary Shares (symbol: NYXH) is at the forefront of medical technology, focusing on innovative solutions to address Obstructive Sleep Apnea (OSA). The company is committed to enhancing the lives of individuals suffering from sleep-disordered breathing conditions through its state-of-the-art products and services.

Nyxoah's flagship product, the Genio system, is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe OSA. This user-centered system provides an effective and non-invasive treatment option for a condition that has been linked to increased mortality risks and various comorbidities, including cardiovascular diseases, depression, and stroke.

The Genio system stands out in the market due to its unique approach, focusing on bilateral stimulation to open the airway during sleep, thereby improving the quality of life for patients. The development and commercialization of this innovative platform underscore Nyxoah's commitment to addressing critical health issues with cutting-edge technology.

Recent achievements of Nyxoah include advancements in clinical trials, expansion into new markets, and strategic partnerships that underscore the company's growth potential and dedication to innovation. Financially, Nyxoah has shown resilience and strategic foresight, ensuring robust investment in research and development to maintain its competitive edge.

Nyxoah continually updates its stakeholders with the latest company news, ensuring transparency and fostering investor confidence. With its headquarters in Belgium, Nyxoah is well-positioned to expand its global presence and continue its mission of providing effective solutions for OSA and related conditions.

Stay informed with the latest updates and developments from Nyxoah to keep track of their performance, events, and strategic initiatives.

News
Rhea-AI Summary

Nyxoah Announces New CFO Appointment

Mont-Saint-Guibert, Belgium – November 8, 2021 - Nyxoah (NYSE: NYXH) appointed Loïc Moreau as its new CFO, effective January 1, 2022. Moreau joins from GSK, where he held significant finance roles. He replaces Fabian Suarez, who is leaving to become CEO of a MedTech startup. CEO Olivier Taelman expressed gratitude for Suarez's contributions, particularly during the company's IPOs on Euronext and Nasdaq. Nyxoah specializes in innovative treatments for Obstructive Sleep Apnea, and its Genio® system has achieved CE Mark approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
management
-
Rhea-AI Summary

Nyxoah announces participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021. CEO Olivier Taelman will engage in a fireside chat at 4:00 pm CET/10:00 am ET. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA) and is known for its lead product, the Genio® system, a leadless and battery-free hypoglossal neurostimulation therapy. The company received its European CE Mark in 2019 and is currently pursuing FDA approval for its devices in the US through the DREAM IDE pivotal study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary

Nyxoah SA has disclosed important information regarding its voting rights and share capital as of October 29, 2021. The total share capital now stands at EUR 4,407,612.69 with a total of 25,657,359 voting rights, all relating to ordinary shares. Additionally, there are 1,400,000 new securities available via 2021 ESOP Warrants, which allows holders to subscribe to these voting rights. This update aligns with the company's obligations under Belgian law concerning shareholder information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
Rhea-AI Summary

Nyxoah SA (NYSE: NYXH) announced on October 4, 2021, the CE-Mark indication approval from DEKRA for its Genio® system to treat Complete Concentric Collapse (CCC) patients. This approval expands their market by at least 30%. The decision is based on positive findings from the BETTER SLEEP study, confirming the effectiveness of the system for CCC patients without needing prior Drug-Induced Sleep Endoscopy. This marks a significant advancement for patients previously excluded from hypoglossal nerve stimulation therapies and boosts Nyxoah's growth prospects in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
-
Rhea-AI Summary

Nyxoah SA announces an increase in share capital following the issuance of 27,000 new shares on September 30, 2021, pursuant to subscription rights. The total share capital is now EUR 4,388,714.69, with a total of 25,547,359 voting rights related to ordinary shares. Additionally, the company discloses information regarding various ESOP warrants that allow holders to subscribe to over 2.2 million additional shares. This announcement aligns with regulations on large shareholdings as outlined in local law.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary

Nyxoah has received FDA Breakthrough Device Designation for its Genio® system, aimed at treating Obstructive Sleep Apnea (OSA) in adults with Complete Concentric Collapse (CCC). This designation facilitates quicker access to innovative therapies, offering priority review and interaction with FDA experts. The designation is supported by results from the BETTER SLEEP trial, which demonstrated safety and effectiveness in OSA patients. This advancement could significantly expand Nyxoah's market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
Rhea-AI Summary

Nyxoah, a medical technology company specializing in innovative solutions for Obstructive Sleep Apnea (OSA), announced its participation in the Cantor 2021 Global Healthcare Conference on September 28, 2021, at 4:00 pm CET/10:00 am ET. CEO Olivier Taelman will present virtually, and a live webcast will be available on the company’s investor relations website. Nyxoah is known for its lead product, the Genio® system, which received the European CE Mark in 2019 following the successful BLAST OSA study. The company is also conducting the DREAM IDE pivotal study for FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
Rhea-AI Summary

On September 12, 2021, Nyxoah SA disclosed the issuance of 1,400,000 new warrants and 82,500 new shares. Following these events, the company's share capital has reached EUR 4,384,076.09 and the total number of securities carrying voting rights is now 25,520,359, all ordinary shares. The number of outstanding subscription rights includes various ESOP warrants issued between 2013 and 2021, entitling holders to subscribe to a total of 1,721,500 additional voting rights. This update is aligned with the Law of 2 May 2007 on large shareholdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
none
-
Rhea-AI Summary

Nyxoah SA (Nasdaq: NYXH) announced its participation in the Baird 2021 Global Healthcare Conference, scheduled for September 14, 2021. CEO Olivier Taelman and CFO Fabian Suarez will present virtually at 3:05 pm CET / 9:05 am ET. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA), with its leading product, the Genio® system, receiving CE Mark approval in 2019 following successful clinical trials. The company is currently conducting the DREAM IDE pivotal study for FDA approval and a European study to confirm the Genio® system's long-term effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
Rhea-AI Summary

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced on September 1, 2021, that it received transparency notifications from Robelga SRL and Together Partnership regarding their shareholdings. Robelga SRL's shareholding fell below 3%, holding 696,000 shares (2.78% of voting rights) as of July 7, 2021. Meanwhile, Together Partnership reported a downward crossing of the 10% threshold, holding 2,503,500 shares (9.84% of voting rights) as of July 9, 2021. The total voting rights for these entities combined represent 11.27% of all voting rights in Nyxoah.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none

FAQ

What is the current stock price of Nyxoah SA Ordinary Shares (NYXH)?

The current stock price of Nyxoah SA Ordinary Shares (NYXH) is $10.83 as of January 21, 2025.

What is the market cap of Nyxoah SA Ordinary Shares (NYXH)?

The market cap of Nyxoah SA Ordinary Shares (NYXH) is approximately 408.3M.

What is Nyxoah SA's core business?

Nyxoah SA focuses on developing and commercializing innovative solutions to treat Obstructive Sleep Apnea (OSA).

What is the Genio system?

The Genio system is a CE-Mark validated, bilateral neurostimulation therapy designed to treat moderate to severe Obstructive Sleep Apnea (OSA).

What conditions does Nyxoah's Genio system address?

The Genio system targets Obstructive Sleep Apnea (OSA), which is associated with increased mortality risk and comorbidities like cardiovascular diseases, depression, and stroke.

How does Nyxoah update its stakeholders?

Nyxoah ensures transparency by continually updating stakeholders with the latest company news, performance information, and strategic initiatives.

Where is Nyxoah SA headquartered?

Nyxoah SA is headquartered in Belgium, with its innovative solutions reaching markets worldwide.

What makes the Genio system unique?

The Genio system is unique due to its bilateral stimulation approach, providing an effective and non-invasive treatment for OSA by opening the airway during sleep.

What recent achievements has Nyxoah accomplished?

Nyxoah has made significant strides in clinical trials, market expansion, and strategic partnerships, highlighting its growth potential and commitment to innovation.

What is OSA?

Obstructive Sleep Apnea (OSA) is a sleep disorder characterized by repeated episodes of partial or complete obstruction of the upper airway during sleep, leading to breathing interruptions.

Why invest in Nyxoah SA?

Nyxoah SA offers innovative solutions for OSA, a condition with significant health risks. The company's continuous advancements, strategic partnerships, and commitment to innovation make it a promising investment opportunity.

What are Nyxoah's future plans?

Nyxoah aims to expand its global presence, enhance its product offerings, and continue investing in research and development to bring effective solutions for sleep-disordered breathing conditions.
Nyxoah SA Ordinary Shares

Nasdaq:NYXH

NYXH Rankings

NYXH Stock Data

408.33M
23.09M
38.32%
32.48%
0.25%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Mont-Saint-Guibert